Sino Biopharmaceutical Limited (OTCMKTS:SBMFF) Sees Significant Growth in Short Interest

Sino Biopharmaceutical Limited (OTCMKTS:SBMFF) saw a large increase in short interest in November. As of November 15th, there was short interest totalling 8,048,300 shares, an increase of 26.8% from the October 31st total of 6,347,300 shares. Based on an average daily trading volume, of 5,400 shares, the short-interest ratio is currently 1,490.4 days.

Sino Biopharmaceutical Trading Down 1.0 %

Shares of OTCMKTS:SBMFF opened at $0.42 on Monday. Sino Biopharmaceutical has a 12-month low of $0.31 and a 12-month high of $0.47. The stock has a fifty day simple moving average of $0.45 and a two-hundred day simple moving average of $0.39.

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.